Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotatercept in children with pulmonary arterial hypertension
NCT05587712Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2023
- Primary completion
- Sep 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 12
01
Overview
A Phase 2 trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Merck & Co.. Started Jan 2023; status: recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05587712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05587712.